Clinical trials - Press Releases

Date	Title	Company
26-Oct-2023	IDP Pharma announces first patient dosed in a Phase 1/2 Clinical Trial of IDP-121, a direct cMyc protein inhibitor and degrader	IDP Pharma
26-Oct-2023	GALDERMA PHASE III DATA PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE: FULL OLYMPIA 2 TRIAL RESULTS DEMONSTRATE NEMOLIZUMAB’S RAPID ONSET OF ACTION IN PRURIGO NODULARIS PATIENTS	Galderma
26-Oct-2023	Immunocore presents three-year overall survival data from the KIMMTRAK Phase 3 trial	Immunocore
26-Oct-2023	Kancera reports that the phase I study of KAND145 has received regulatory approval	Kancera AB
26-Oct-2023	Landmark Phase 3 MARIPOSA Study Shows RYBREVANT®▼(amivantamab) Plus Lazertinib Resulted in 30 Percent Reduction in Risk of Disease Progression or Death Compared to Osimertinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer	Janssen Pharmaceutical Companies of Johnson & Johnson
26-Oct-2023	Phase 3 MARIPOSA-2 Study Shows RYBREVANT®▼(amivantamab) Plus Chemotherapy Given with or without Lazertinib Reduced Risk of Disease Progression or Death by 56 and 52 Percent Respectively in Patients with EGFRMutated Non-Small Cell Lung Cancer who Progressed on or after Osimertinib	Janssen Pharmaceutical Companies of Johnson & Johnson
26-Oct-2023	Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Dosed First Patient in Phase 2 Trial with BI 764532 in Small Cell Lung Cancer and other Neuroendocrine Cancers	Oxford BioTherapeutics
26-Oct-2023	PharmaKure submits MHRA CTA for Phase 2a Clinical Trial of PK051 in patients with mild cognitive impairment	PharmaKure
24-Oct-2023	NKGen Biotech Announces FDA Clearance of Investigational New Drug Application for SNK01 NK Cell Therapy to Treat Alzheimer’s Disease	NKGen Biotech
24-Oct-2023	ImmunOs Therapeutics Presents Overview of Phase 1a/b Trial of Lead Compound IOS-1002	ImmunOs Therapeutics
19-Oct-2023	Avance Clinical Invited to Brief 45 Korean Biotechs on Their GlobalReady Drug Development Pathway from Korea and Australia to the US	Avance Clinical
18-Oct-2023	TrialAssure Uses Artificial Intelligence to Create Plain Language Summaries for 50,000 Studies Listed on ClinicalTrials.Gov	TrialAssure
17-Oct-2023	New publication shows XF-73 drug potent against 2,527 Staphylococcus isolates Largest study of its kind to date demonstrates effectiveness of XF-73 against all tested antibiotic resistant strains	Destiny Pharma
17-Oct-2023	STORM Therapeutics Presented Novel Pre-Clinical Data on STC-15 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics	STORM Therapeutics Ltd
17-Oct-2023	Leading Proxy Advisor, ISS, Recommends Shareholders Vote “FOR” Danaher Corporation’s Proposed Acquisition of Abcam	Abcam plc
17-Oct-2023	PATIENTS DOSED WITH METHYLONE IN LONDON IN NEW CLINICAL TRIAL TO TREAT PTSD	Clerkenwell Health
17-Oct-2023	Cherwell to participate in sterile product manufacturing think tank discussions	Cherwell
17-Oct-2023	AI startup Leucine nets $7M to level up Pharma manufacturing compliance to keep pace with drug innovation	Leucine nets $7M to level up pharma manufacturing compliance to keep pace with drug innovation
17-Oct-2023	Tilray Medical Supports New Clinical Trial to Study Medical Cannabis in Glioblastoma Cancer Treatment	Tilray Medical
17-Oct-2023	CD BioSciences Launches New 3D Tissue Imaging Services	CD BioSciences